MedTrace Logo

Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia Using Carbetocin Versus Misoprostol

NCT02086994 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-02-15

No results posted yet for this study

Summary

We aim to compare carbetocin with misoprostol for the prevention of postpartum hemorrhage in patients with severe preeclampsia. The primary outcome is postpartum haemorrhage (blood loss of ≥ 500 ml) while our Secondary outcomes include use of additional uterotonics, need for blood transfusion, maternal adverse drug reaction, maternal complications and maternal death

Conditions

  • Severe Pre-eclampsia, Postpartum Condition or Complication

Interventions

DRUG

misoprostol

given after the delivery of the anterior shoulder of the baby.

DRUG

carbetocin

given after delivery of anterior shoulder

Sponsors & Collaborators

  • khalid abd aziz mohamed

    lead OTHER

Principal Investigators

  • khalid mohamed, MD · lecturer of ob/gyn Benha faculty of medicine

  • ahmed sasd, MD · lecturer

  • ahmed walid · assistant profossor

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02086994 on ClinicalTrials.gov